Trial Profile

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab/pembrolizumab (Primary) ; Gebasaxturev (Primary) ; MK-4830 (Primary) ; Pembrolizumab (Primary) ; Tretinoin (Primary) ; Vibostolimab (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms KEYMAKER-U02; Substudy 02C
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

01 Jan 2025 Results from the first three arms, published in the Nature Medicine.
20 Dec 2023 Status changed from recruiting to active, no longer recruiting.
19 Apr 2023 Results ( At data cutoff September 9, 2022, n=66 )presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com